Cardinal Health Inc

CAH

214.880USD

+3.650+1.73%

Close 01/30, 16:00（ET）Quotes delayed by 15 min

Cardinal Health Inc's Score

Industry at a Glance

Industry Ranking

7 / 159

Overall Ranking

26 / 4536

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Cardinal Health Inc Highlights

StrengthsRisks

Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 222.58B.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 222.58B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 31.52%.

Fairly Valued

The company’s latest PE is 32.28, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 215.79M shares, decreasing 0.05% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 3.33K shares of this stock.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

233.771

Target Price

+10.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Cardinal Health Inc is 8.99, ranking 22 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 64.01B, representing a year-over-year increase of 22.44%, while its net profit experienced a year-over-year increase of 8.17%.

Score

Industry at a Glance

Previous score

8.99

Change

0



Financials

5.57

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.84

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Cardinal Health Inc is 5.45, ranking 146 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 32.28, which is 313.05% below the recent high of 133.35 and 154.19% above the recent low of -17.50.

Score

Industry at a Glance

Previous score

5.45

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 7/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Cardinal Health Inc is 8.44, ranking 35 out of 159 in the Pharmaceuticals industry. The average price target is 220.00, with a high of 243.00 and a low of 152.11.

Score

Industry at a Glance

Previous score

8.44

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Cardinal Health Inc is 9.61, ranking 7 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 220.94 and the support level at 204.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.16

Change

0.45

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-01-30

The current institutional shareholding score of Cardinal Health Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 91.00%, representing a quarter-over-quarter decrease of 0.60%. The largest institutional shareholder is The Vanguard, holding a total of 31.33M shares, representing 13.19% of shares outstanding, with 2.73% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

30.71M

+0.80%

BlackRock Institutional Trust Company, N.A.

15.06M

+2.57%

State Street Investment Management (US)

12.29M

-3.04%

Geode Capital Management, L.L.C.

6.49M

+1.50%

Wellington Management Company, LLP

5.80M

+153.18%

BlackRock Financial Management, Inc.

5.69M

+13.56%

Fidelity Management & Research Company LLC

4.71M

-12.43%

Norges Bank Investment Management (NBIM)

3.48M

+66.74%

Invesco Capital Management LLC

Star Investors

2.91M

+12.85%

BlackRock Investment Management, LLC

2.86M

-10.53%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cardinal Health Inc is 9.07, ranking 17 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Cardinal Health Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Cardinal Health Inc

CAH

8.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

8.98 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.93 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.80 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.74 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

ANI Pharmaceuticals Inc

ANIP

8.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment